Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 62

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 62
---
Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form
10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,”
“believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended
to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results
may differ materially depending on a variety of factors, many of which are not within our control. These factors include but are not limited
to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including
competition from much larger competitors; technological advances and failure to successfully develop business relationships.

Description of Business

Overview

Our objective is to develop
and commercialize our product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing
to disease. Immune dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays
a significant role in the development of immune dysfunction. Immune dysfunction can be seen in cancer where Natural Killer (“NK”)
cells are impaired and facilitate a tumor’s evasion of the immune system and subsequent disease progression. Chronic inflammation
is implicated in various diseases, where it impairs the immune system. Our primary focus continues to be treatment of Alzheimer’s
Disease (“AD”) with XPro1595 (“XPro™ and DN-TNF) and treatment of recessive dystrophic epidermolysis bullosa (“RDEB”)
with CORDStrom, a proprietary, pooled, human umbilical cord mesenchymal stromal cell platform. RDEB is a pediatric orphan disease caused
by mutations in the COL7A1 gene which results in highly debilitating skin blistering, dysphagia and failure to thrive with chronic wound
problems that often result in fatal squamous cell carcinoma.

XPro for AD has completed
Phase I and Phase II trials with enrollment of patients at clinical sites in the United Kingdom, EU, Australia and Canada. The INKmune
program has nearly completed an open label Phase II trial in metastatic castrate